Chongqing Renze Pharmaceutical Technology

Chongqing Renze Pharmaceutical Technology is a China-based pharmaceutical company founded in 2017 that specializes in the research, development, and commercialization of high-end pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Operating as a Marketing Authorization Holder (MAH) with a "B" license, the company focuses on small molecule drug development across therapeutic areas such as cardiovascular disease, oncology, and anesthesiology. Their portfolio includes commercialized products like Torasemide tablets and a robust pipeline of APIs including Rocuronium bromide and Enzalutamide. Renze Pharmaceutical provides comprehensive CRO and CDMO services, leveraging a team of experienced researchers to support complex chemical synthesis, process optimization, and regulatory registration. The company is recognized as a National High-tech Enterprise and is a key player in the Chongqing biopharmaceutical innovation cluster.